Comparative Clinical Pathology

, Volume 28, Issue 4, pp 1077–1085 | Cite as

Comparison of transduction efficiency among various cell types by a lentivector containing CMV promoter

  • Hori GhaneialvarEmail author
  • Abbas Sahebghadam Lotfi
  • Sareh Arjmand
  • Leila Soltani
  • Azra Kenarkoohi
  • Mohammad Mahdi Zangeneh
Original Article


Due to their unique biological characteristics, mesenchymal stem cells (MSCs) are useful in developing cell-based therapies, tissue regeneration, and many other applications of cellular and molecular genetics. Use of lentiviral system allows the integration of specific nucleic acid sequence into a target cell genome near an active transcription site in such a way that it is stable and heritable. The aim of the present study was to evaluate the gene transduction efficiency on the cells of different species using lentivirus along with cytomegalovirus in a lentiviral shuttle vector. In this study, the third-passage isolated MSCs from four different species, including ovine and goat cardiac fibroblasts, HEK293T, and L929 cell line were transduced by concentrated virus particles. Then, transduction percentage was detected by flow cytometry. The findings showed different transduction efficiencies for various cells of one species or other species, indicating that differentiated and undifferentiated cells had different transduction percentages. Different degrees of transduction observed in differentiated and undifferentiated cells might be the result of various lentiviral receptors on the plasma membrane, site of integration, and activity of CMV promoter. Further, other regulatory factors involved in cell transduction and target gene expression can cause different percentages of transduction.


Mesenchymal stem cells Cell therapy Lentiviral vectors Gene therapy Transfection 



We sincerely thank Mr. Jedi, the manager of Rock slaughterhouse for his generous support of providing the samples.


The authors would like to thank the Ilam University of Medical Science for the financial support.

Compliance with ethical standards

Conflict of interests

The authors declare that they have no conflict of interest.

Ethic approval

All institutional and national guidelines for the care and use of human and laboratory animals were followed.


  1. Al-Dosari MS, Gao X (2009) Nonviral gene delivery: principle, limitations, and recent progress. AAPS J 11(4):671Google Scholar
  2. Amado RG, Chen ISY (1999) Lentiviral vectors the promise of gene therapy within reach? Science 285(5428):674–676Google Scholar
  3. Arinzeh TL, Peter SJ, Archambault MP, van den Bos C, Gordon S, Kraus K, Smith A, Kadiyala S (2003) Allogeneic mesenchymal stem cells regenerate bone in a critical-sized canine segmental defect. J Bone Joint Surg Am 85(10):1927–1935Google Scholar
  4. Baksh D, Song L, Tuan RS (2004) Adult mesenchymal stem cells: characterization, differentiation, and application in cell and gene therapy. J Cell Mol Med 8(3):301–316Google Scholar
  5. Borok Z, Harboe-Schmidt JH, Brody S, You Y, Zhou B, Li X, Cannon PM, Kim KJ, Crandall ED, Kasahara N (2001) Vesicular stomatitis virus G-pseudotyped lentivirus vectors mediate efficient apical transduction of polarized quiescent primary alveolar epithelial cells. J Virol 75(3):11747–11754Google Scholar
  6. Chamberlain JR, Schwarze U, Wang PR, Hirata RK, Hankenson KD, Pace JM, Underwood RA, Song KM, Sussman M, Byers PH, Russell DW (2004) Gene targeting in stem cells from individuals with osteogenesis imperfecta. Science 303(5661):1198–1201Google Scholar
  7. Chung S, Andersson T, Sonntag KC, Björklund L, Isacson O, Kim KS (2002) Analysis of different promoter systems for efficient transgene expression in mouse embryonic stem cell lines. Stem Cells 20(2):139–145Google Scholar
  8. Crevensten G, Walsh AJ, Ananthakrishnan D, Page P, Wahba GM, Lotz JC, Berven S (2004) Intervertebral disc cell therapy for regeneration: mesenchymal stem cell implantation in rat intervertebral discs. Ann Biomed Eng 32(3):430–434Google Scholar
  9. Cronin J, Zhang XY, Reiser J (2005) Altering the tropism of lentiviral vectors through pseudotyping. Curr Gene Ther 5(4):387–398Google Scholar
  10. Davidson BL, Breakefield XO (2003) Viral vectors for gene delivery to the nervous system. Nat Rev Neurosci 4(5):353–364Google Scholar
  11. Davis BM, Humeau L, Slepushkin V, Binder G, Korshalla L, Ni Y, Ogunjimi EO, Chang LF, Lu X, Dropulic B (2004) ABC transporter inhibitors that are substrates enhance lentiviral vector transduction into primitive hematopoietic progenitor cells. Blood 104(2):364–373Google Scholar
  12. Daya S, Berns KI (2008) Gene therapy using adeno-associated virus vectors. Clin Microbiol Rev 21(4):583–593Google Scholar
  13. Frecha C, Lévy C, Cosset FL, Verhoeyen E (2010) Advances in the field of lentivector-based transduction of T and B lymphocytes for gene therapy. Mol Ther 18(10):1748–1757Google Scholar
  14. Golden HB, Gollapudi D, Gerilechaogetu F, Li J, Cristales RJ, Peng X, Dostal DE (2012) Isolation of cardiac myocytes and fibroblasts from neonatal rat pups. In: Peng X, Antonyak M (eds) Cardiovascular development: methods and protocols. Humana press, Totowa, pp 205–214Google Scholar
  15. Hanawa H, Kelly PF, Nathwani AC, Persons DA, Vandergriff JA, Hargrove P, Vanin EF, Nienhuis AW (2002) Comparison of various envelope proteins for their ability to pseudotype lentiviral vectors and transduce primitive hematopoietic cells from human blood. Mol Ther 5(3):242–251Google Scholar
  16. Hong S, Hwang DY, Yoon S, Isacson O, Ramezani A, Hawley RG, Kim KS (2007) Functional analysis of various promoters in lentiviral vectors at different stages of in vitro differentiation of mouse embryonic stem cells. Mol Ther 15(9):1630–1639Google Scholar
  17. Kamimura K, Suda T, Zhang G, Liu D (2011) Advances in gene delivery systems. Pharm Med 25(5):293–306Google Scholar
  18. Karussis D, Karageorgiou C, Vaknin-Dembinsky A, Gowda-Kurkalli B, Gomori JM, Kassis I, Bulte JW, Petrou P, Ben-Hur T, Abramsky O, Slavin S (2010) Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Arch Neurol 67(10):1187–1194Google Scholar
  19. Keating AHW, Hawley RG, Toneguzzo F (1990) Effect of different promoters on expression of genes introduced into hematopoietic and marrow stromal cells by electroporation. Exp Hematol 18(2):99–102Google Scholar
  20. Lee CI, Kohn DB, Ekert JE, Tarantal AF (2004) Morphological analysis and lentiviral transduction of fetal monkey bone marrow-derived mesenchymal stem cells. Mol Ther 9(1):112–123Google Scholar
  21. Li M, Husic N, Lin Y, Malik I, McIver S, LaPash Daniels CM, Harris DA, Kotzbauer PT, Goldberg MP, Snider BJ (2010) Optimal promoter usage for lentiviral vector-mediated transduction of cultured central nervous system cells. J Neurosci Methods 189(1):56–64Google Scholar
  22. Liew CG, Draper JS, Walsh J, Moore H, Andrews PW (2007) Transient and stable transgene expression in human embryonic stem cells. Stem Cell 25(6):1521–1528Google Scholar
  23. Madeira C, Mendes RD, Ribeiro SC, Boura JS, Aires-Barros MR, da Silva CL, Cabral JMS (2010) Nonviral gene delivery to mesenchymal stem cells using cationic liposomes for gene and cell therapy. J Biomed Biotechnol 12Google Scholar
  24. Mali S (2013) Delivery systems for gene therapy. Int J Hum Genet 19(1):3–8Google Scholar
  25. Morando S, Vigo T, Esposito M, Casazza S, Novi G, Principato MC, Furlan R, Uccelli A (2012) The therapeutic effect of mesenchymal stem cell transplantation in experimental autoimmune encephalomyelitis is mediated by peripheral and central mechanisms. Stem Cell Res Ther 3(1):1–7Google Scholar
  26. Muller SR, Sullivan PD, Clegg DO, Feinstein SC (1990) Efficient transfection and expression of heterologous genes in PC12 cells. DNA Cell Biol 9(3):221–229Google Scholar
  27. Nouri N, Talebi M, Palizban AA (2012) Viral and nonviral delivery systems for gene delivery. Adv Biomed Res 1:27Google Scholar
  28. Okita K, Nakagawa M, Hyenjong H, Ichisaka T, Yamanaka S (2008) Generation of mouse induced pluripotent stem cells without viral vectors. Science 322(903):949–953Google Scholar
  29. Qin JY, Zhang L, Clift KL, Hulur I, Xiang AP, Ren BZ, Lahn BT (2010) Systematic comparison of constitutive promoters and the doxycycline-inducible promoter. PLoS One 5(5):e10611Google Scholar
  30. Ramamoorth M, Narvekar A (2015) Non viral vectors in gene therapy an overview. J Clin Diagn Res 9(1):1–6Google Scholar
  31. Reiser J, Zhang XY, Hemenway CS, Mondal D, Pradhan L, La Russa VF (2005) Potential of mesenchymal stem cells in gene therapy approaches for inherited and acquired diseases. Expert Opin Biol Ther 5(12):1571–1584Google Scholar
  32. Schmidt EV, Christoph G, Zeller R, Leder P (1990) The cytomegalovirus enhancer: AP an active control element in transgenic mice. Mol Cell Biol 10(8):4406–4411Google Scholar
  33. Soda Y, Tani K, Li X, Bai Y, Cho SG, Futami M, Chen M, Kobayashi S, Miyoshi H, Sumimoto H, Ohga S, Hara T, Tojo A, Asano S (2005) 103. PGK and CMV promoters exert the strongest activity in lentiviral gene transduction of myeloid cells including mature neutrophils. Mol Ther 11(1):42Google Scholar
  34. Thomas CE, Ehrhardt A, Kay MA (2003) Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet 4(5):346–358Google Scholar
  35. Totsugawa TKN, Okitsu T, Noguchi H, Noguchi H, Watanabe T, Matsumura T, Maruyama M, Fujiwara T, Sakaguchi M, Tanaka N (2002) Lentiviral transfer of the Lac Z gene into human endothelial cells and human bone marrow mesenchymal stem cells. Cell Transplant 11(5):481–488Google Scholar
  36. Verma IM, Somia N (1997) Gene therapy promises, problems and prospects. Nature 389(6648):239–242Google Scholar
  37. Vollweiler JL, Zielske SP, Reese JS, Gerson SL (2003) Hematopoietic stem cell gene therapy: progress toward therapeutic targets. Bone Marrow Transplant 32(1):1–7Google Scholar
  38. Wei X, Yang X, Han ZP, Qu FF, Shao L, Shi YF (2013) Mesenchymal stem cells: a new trend for cell therapy. Acta Pharmacol Sin 34(6):747–754Google Scholar
  39. Zhang XY, La Russa VF, Reiser J (2004) Transduction of bone-marrow-derived mesenchymal stem cells by using lentivirus vectors pseudo typed with modified RD114 envelope glycoproteins. J Virol 78(3):1219–1229Google Scholar

Copyright information

© Springer-Verlag London Ltd., part of Springer Nature 2019

Authors and Affiliations

  1. 1.Biotechnology and Medicinal Plants Research Center, Faculty of MedicineIlam University of Medical SciencesIlamIran
  2. 2.Department of Clinical Biochemistry, Faculty of MedicineIlam University of Medical SciencesIlamIran
  3. 3.Department of Clinical Biochemistry, Faculty of Medical SciencesTarbiat Modares UniversityTehranIran
  4. 4.Protein Research CenterShahid Beheshti UniversityTehranIran
  5. 5.Department of Animal Science, College of AgricultureIsfahan University of TechnologyIsfahanIran
  6. 6.Department of Microbiology, Faculty of MedicineIlam University of Medical SciencesIlamIran
  7. 7.Department of Clinical Science, Faculty of Veterinary MedicineRazi UniversityKermanshahIran

Personalised recommendations